Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

708
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
708
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lateral Transport in Anisotropic Membrane during Permeation Study in Diffusion Cell.

Pharmaceutical research·2026
Same author

Inhibition of Endothelial Cell Tube Formation by Anti-Vascular Endothelial Growth Factor/Anti-Angiopoietin-2 RNA Nanoparticles.

Pharmaceutics·2025
Same author

Supramolecular H-Aggregates of Squaraines with Enhanced Type I Photosensitization for Combined Photodynamic and Photothermal Therapy.

ACS nano·2024
Same author

Engineering PTS-based glucose metabolism for efficient biosynthesis of bacterial cellulose by Komagataeibacter xylinus.

Carbohydrate polymers·2024
Same author

Engineering Shewanella oneidensis-Carbon Felt Biohybrid Electrode Decorated with Bacterial Cellulose Aerogel-Electropolymerized Anthraquinone to Boost Energy and Chemicals Production.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2024
Same author

Phenotyping of FGF12A<sup>V52H</sup> mutation in mouse implies a complex FGF12 network.

Neurobiology of disease·2024

Related Experiment Video

Updated: Jan 13, 2026

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

881

Targeting the Eye: RNA-Based Therapies, Interferences, and Delivery Strategies.

Mohammed S Abdel-Raziq Hassan1, Cheng Zhong2, Fatma Hassan1

  • 1Department of Chemistry, College of Arts and Sciences, University of Cincinnati, Cincinnati, OH 45221, USA.

Pharmaceutics
|October 29, 2025
PubMed
Summary

RNA therapeutics offer a promising new way to treat eye diseases by targeting their root causes. While challenges remain, RNA aptamers, siRNA, and ASOs show potential for conditions like AMD and glaucoma.

Keywords:
RNA aptamerRNA nanotechnologyantisense oligonucleotideseyemiRNAposterior eye diseaseshRNAsiRNA

More Related Videos

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models
06:16

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

3.6K
Intravitreal Injections in the Ovine Eye
03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

3.9K

Related Experiment Videos

Last Updated: Jan 13, 2026

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

881
Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models
06:16

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

3.6K
Intravitreal Injections in the Ovine Eye
03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

3.9K

Area of Science:

  • Molecular Biology
  • Ophthalmology
  • Genetics

Background:

  • RNA-based therapeutics are emerging as a powerful tool for treating eye diseases.
  • Current RNA technologies include aptamers, antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and messenger RNA (mRNA).
  • RNA tools also aid in understanding disease mechanisms, expanding therapeutic possibilities.

Purpose of the Study:

  • To review RNA interference and related ocular delivery for posterior eye diseases.
  • To focus on RNA aptamers, siRNA, short hairpin RNA (shRNA), and microRNA (miRNA) applications.
  • To discuss RNA's role in advancing understanding and treatment of posterior segment eye diseases.

Main Methods:

  • Review of RNA interference mechanisms and ocular delivery systems.
  • Analysis of RNA aptamer, siRNA, shRNA, and miRNA applications in ophthalmology.
  • Discussion of RNA-based therapeutic strategies for posterior eye diseases.

Main Results:

  • RNA therapeutics can target specific molecular pathways in eye disorders.
  • siRNA, shRNA, miRNA, and ASOs silence disease-driving genes; RNA aptamers bind specific targets.
  • Promising results for age-related macular degeneration (AMD), diabetic macular edema (DME), glaucoma, and inherited retinal disorders.

Conclusions:

  • RNA therapeutics provide a novel approach to treating eye diseases by addressing molecular origins.
  • Effective delivery and long-term safety are critical challenges for clinical translation.
  • RNA-based therapies hold significant promise for various ocular conditions despite being in early stages.